Abstract: A product comprising a first compartment and a second compartment. The first compartment has first walls that define a reservoir. The first compartment includes a first lid enclosing a medicament within the reservoir. The second compartment has second walls that define a cavity. The second compartment includes a second lid enclosing a glove within the cavity. The first compartment and the second compartment are coupled together with the reservoir and the cavity separated and sealed from one another. The first walls of the first compartment and the second walls of the second compartment are semi-rigid or rigid.

Abstract: Provided herein are high-dose formulations of acamprosate in a pharmaceutically acceptable salt form, as well as methods of preparing the same, and methods of using the same.

Abstract: A product comprising a first compartment and a second compartment. The first compartment has first walls that define a reservoir. The first compartment includes a first lid enclosing a medicament within the reservoir. The second compartment has second walls that define a cavity. The second compartment includes a second lid enclosing a glove within the cavity. The first compartment and the second compartment are coupled together with the reservoir and the cavity separated and sealed from one another. The first walls of the first compartment and the second walls of the second compartment are semi-rigid or rigid.

Abstract: Embodiments described herein generally relate to improved devices, systems, kits, products and methods related to topical medicament application of measured dosages. The kits and devices can single use and/or disposable for example.

Abstract: Systems and methods are presented for providing personalized prognostic profiles. Personalized prognostic profiles corresponding to the person of interest are generated and include: a personalized prognostic graph showing the historical outcomes of a matched population that is a subset of a reference population over a display interval; a widget containing identifying information about the index patient, indicating the forced match variables, the time interval(s) of interest, and the treatment of interest if applicable, and one or more supplemental widgets providing further information concerning the index patient's clinical status, care received, care plans, care preferences, or issues related to illness-related clinical or personal concerns of the index patient.

Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations optionally in combination with at least one other medication, and to combination products and compositions comprising acamprosate and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.

Abstract: Embodiments disclosed herein generally relate to methods of treating posttraumatic stress disorder (PTSD) using acamprosate formulations and/or acamprosate formulations in combination with at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.

Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations optionally in combination with at least one other medication, and to combination products and compositions comprising acamprosate and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.

Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.

Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.

Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.

Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.

Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations optionally in combination with at least one other medication, and to combination products and compositions comprising acamprosate and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.

Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations optionally in combination with at least one other medication, and to combination products and compositions comprising acamprosate and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.

Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.

Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.

Abstract: Embodiments described herein generally relate to improved devices, systems, kits, products and methods related to topical medicament application of measured dosages. The kits and devices can single use and/or disposable for example.

Abstract: Embodiments described herein generally relate to improved devices, systems, kits, products and methods related to topical medicament application of measured dosages. The kits and devices can single use and/or disposable for example.

Abstract: Embodiments described herein generally relate to improved devices, systems, kits, products and methods related to topical medicament application of measured dosages. The kits and devices can single use and/or disposable for example.

Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.